DekaBank Deutsche Girozentrale Has $731.46 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

DekaBank Deutsche Girozentrale lifted its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 1.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,483,071 shares of the company's stock after purchasing an additional 71,750 shares during the quarter. Johnson & Johnson makes up about 1.4% of DekaBank Deutsche Girozentrale's investment portfolio, making the stock its 9th largest position. DekaBank Deutsche Girozentrale owned 0.19% of Johnson & Johnson worth $731,462,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the company. Lantz Financial LLC boosted its stake in Johnson & Johnson by 3.3% in the 1st quarter. Lantz Financial LLC now owns 11,974 shares of the company's stock valued at $1,986,000 after buying an additional 377 shares in the last quarter. Sulzberger Capital Advisors Inc. acquired a new position in Johnson & Johnson in the fourth quarter worth $453,000. Joel Isaacson & Co. LLC boosted its stake in Johnson & Johnson by 3.5% in the first quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock worth $12,294,000 after purchasing an additional 2,526 shares in the last quarter. State of Wyoming boosted its stake in Johnson & Johnson by 205,580.0% in the fourth quarter. State of Wyoming now owns 10,284 shares of the company's stock worth $1,487,000 after purchasing an additional 10,279 shares in the last quarter. Finally, Range Financial Group LLC boosted its stake in Johnson & Johnson by 18.9% in the first quarter. Range Financial Group LLC now owns 15,886 shares of the company's stock worth $2,635,000 after purchasing an additional 2,529 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Stock Down 0.5%

Shares of NYSE:JNJ traded down $0.82 during mid-day trading on Friday, reaching $156.87. 7,866,488 shares of the stock were exchanged, compared to its average volume of 8,077,942. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. The company has a market cap of $377.44 billion, a P/E ratio of 17.45, a P/E/G ratio of 2.14 and a beta of 0.41. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The stock's 50 day simple moving average is $153.75 and its 200-day simple moving average is $154.55.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. The business had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. As a group, equities research analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 3.31%. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date was Tuesday, May 27th. Johnson & Johnson's dividend payout ratio (DPR) is currently 57.84%.

Analyst Ratings Changes

JNJ has been the topic of a number of recent analyst reports. Raymond James Financial reduced their price objective on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research note on Monday, April 14th. Barclays reduced their price objective on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 17th. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Morgan Stanley reaffirmed an "underperform" rating on shares of Johnson & Johnson in a research note on Thursday. Finally, Leerink Partners lowered Johnson & Johnson from an "outperform" rating to a "market perform" rating and cut their price target for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Eleven equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Johnson & Johnson currently has an average rating of "Moderate Buy" and a consensus price target of $171.00.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.